The Role of RANK/RANKL/OPG Signalling Pathways in Osteoclastogenesis in Odontogenic Keratocysts, Radicular Cysts, and Ameloblastomas

Head and Neck Pathology

Volumn 5, Issue 3, 2011, Pages 248-253

  Tekkesin, Merva Soluk ^a   Mutlu, Sevcihan ^a   Olgac, Vakur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ameloblastomas; Odontogenic keratocyst; OPG; RANK; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADULT; AMELOBLASTOMA; ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; JAW TUMOR; MALE; METABOLISM; MIDDLE AGED; ODONTOGENIC CYST; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; SIGNAL TRANSDUCTION;

ADULT; AMELOBLASTOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAW NEOPLASMS; MALE; MIDDLE AGED; ODONTOGENIC CYSTS; OSTEOCLASTS; OSTEOLYSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION;

EID: 80052792735     PISSN: 1936055X     EISSN: 19360568     Source Type: Journal    
DOI: 10.1007/s12105-011-0271-1     Document Type: Article

References (26)

1. Kurban S, Mehmetoglu I. Osteoprotegerin, RANK and RANK ligand. Turk J Biochem. 2007; 34(4): 178-84.
2. Stejskal D, Bartek J, Pastorková R, et al. Osteoprotegerin, RANK, RANKL. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001; 145(2): 61-4.
3. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology. 2000; 142(12): 5050-5.
4. Kostenuik PJ, Shalhoub V. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des. 2001; 7(8): 613-35.
5. Blai{dotless}r JM, Zheng Y, Dunstan CR. RANK ligand. Int J Biochem Cell Biol. 2007; 39: 1077-81.
6. Chamoux E, Houde N, L'eriger K, et al. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol. 2008; 216: 536-42.
7. Boyce BF, Xing L. Function of RANKL/RANK/OPG in bone modeling end remodeling. Arch Biochem Biophys. 2008; 473(2): 139-46.
8. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-Kb ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer. 2001; 92(3): 460-70.
9. Da Silva TA, Batista AC, Mendonça EF, et al. Comparative expression of RANK, RANKL, and OPG in keratocystic odontogenic tumors, ameloblastomas, and dentigerous cysts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105(3): 333-41.
10. Sandra F, Hendarmin L, Kukita T, et al. Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. Oral Oncol. 2005; 41(6): 637-44.
11. Wang YP, Liu BY. High expression of osteopontin and CD44v6 in odontogenic keratocysts. J Formos Med Assoc. 2009; 108(4): 286-92.
12. Kumamoto H, Ooya K. Expression of paratyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-κB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. J Oral Pathol Med. 2004; 33: 46-52.
13. Shear M, Speight PM. Cysts of the oral and maxillofacial regions. 4th ed. Singapore: Blackwell Munksgaard; 2007. p. 6-58, 123-41.
14. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and maxillofacial pathology. 3th ed. Missouri: Saunders Elsevier; 2009. p. 131-35, 678-91.
15. Philipsen HP. Keratocystic odontogenic tumour. In: Barnes L, Eveson JW, Reichart P, Sinransky D, editors. Head and neck tumours, WHO classification of tumours. 5th ed. Lyon: IARC Press; 2005. p. 306-7.
16. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20(3): 345-57.
17. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998; 253: 395-400.
18. Wise GE, Lumpkin SJ, Huang H, et al. Osteoprotegerin and osteoclast differentiation factor in tooth eruption. J Dent Res. 2000; 79(12): 1937-42.
19. Rani CS, Macdougall M. Dental cells express factors that regulate bone resorption. Mol Cell Biol Res Commun. 2000; 3(3): 145-52.
20. Kanzaki H, Chiba M, Shimizu Y, et al. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. J Dent Res. 2001; 80(3): 887-91.
21. Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trend Mol Med. 2006; 12(1): 17-25.
22. Hamdy NA. Osteoprotegerin as a potential therapy for osteoporosis. Curr Osteoporos Rep. 2005; 3: 121-5.
23. Wittrant Y, Théoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 2004; 1704(2): 49-57.
24. Taubman MA, Valverde P, Han X, Kawai T. Immune response: the key to bone resorption in periodontal disease. J Periodontol. 2005; 76(11): 2033-41.
25. Menezes R, Bramante CM, Da Silva Paiva KB, et al. Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 102(3): 404-9.
26. Gardner DG, Heikinheimo K, Shear M, et al. Ameloblastomas. In: Barnes L, Eveson JW, Reichart P, Sinransky D, editors. WHO classification of tumours. Pathology and genetics of head and neck tumour. 5th ed. Lyon: IARC Press; 2005. p. 296-300.